The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
The increased chemosensitivity of oligodendroglial tumours has been associated with loss of heterozygosity (LOH) of the p arm of chromosome 1 and the q arm of chromosome 19 (LOH 1p/19q). Other clinical and molecular factors have also been identified as being prognostic and predictive of treatment outcome. We reviewed 105 patients with oligodendroglioma treated at a single centre over 20 years. Median survival in oligodendroglioma patients with LOH 1p/19q was significantly longer (10.9 vs. 2.0 years). In the anaplastic oligodendroglioma group, univariate analysis demonstrated decreased patient age, presentation with seizures, use of adjuvant chemotherapy and LOH 1p/19q as predictors of improved survival. Multivariate analysis confirmed LOH 1p/19q as a significant predictor of improved survival (hazard ratio, 3.4; p=0.015). Median survival in patients with anaplastic oligodendroglioma with LOH 1p/19q was 15.4 years vs. 1.2 years for those without LOH 1p/19q. This study confirms the utility of LOH 1p/19q as a prognostic marker in oligodendroglioma.
Cerebral Tumour Research Laboratory, Hormones and Cancer Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Pacific Highway, St Leonards, New South Wales, Australia. jparkinson@med.usyd.edu.au
Jonathon F
JF
Parkinson
Vahid
V
Afaghi
Cathy A
CA
Payne
Michael E
ME
Buckland
Janice M
JM
Brewer
Michael T
MT
Biggs
Nicholas S
NS
Little
Helen R
HR
Wheeler
Raymond J
RJ
Cook
Kerrie L
KL
McDonald
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D002888:Chromosomes, Human, Pair 19 / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D019656:Loss of Heterozygosity; D008297:Male; D008875:Middle Aged; D009837:Oligodendroglioma / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D011379:Prognosis; D016016:Proportional Hazards Models; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D055815:Young Adult
D016159:Tumor Suppressor Protein p53